US FDA approves pemigatinib for treatment of patients with cholangiocarcinoma
Approval was based on a RCT (n=107) in which patients received pemigatinib once a day for 14 days, followed by 7 days off, in 21-day cycles until the disease progressed or the patient experienced an unreasonable level of side effects.
Source:
US Food and Drug Administration
SPS commentary:
Pemigatinib is an inhibitor of fibroblast growth factor receptor (isoforms 1 2 and 3). A marketing authorisation application has also been filed with the European Medicines Agency.